UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
|
|
|
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered |
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On April 21, 2020, Allakos Inc. (the “Company”) issued a press release announcing upcoming presentations related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Allakos Inc. |
|
|
|
|
|
|
|
Date: April 21, 2020 |
|
By: |
/s/ Robert Alexander |
|
|
|
|
Robert Alexander |
|
|
|
|
Chief Executive Officer |
2
Exhibit 99.1
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting
REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting.
The presentations will take place during the DDW Annual Meeting being held virtually from May 2 to 5, 2020. Access to all accepted abstracts, ePosters and ePapers will be available starting May 2 from the DDW ePosters and ePapers website. In addition, abstracts will publish in the May online supplement to Gastroenterology.
Oral Presentations:
|
Title (Presenter): |
Interim Results of an Open-Label Extension Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Eosinophilic Gastritis and/or Eosinophilic Enteritis (Nirmala Gonsalves, MD) |
|
Session (Time): |
Esophageal Diseases, Eosinophilic Esophagitis: Clinical (May 2, 2:30pm CT) |
|
Title (Presenter): |
Histologic and Symptomatic Improvement Across Multiple Forms of Eosinophilic Gastrointestinal Diseases in ENIGMA, A Randomized, Double-Blind, Placebo-Controlled Trial of Antolimab (AK002) (Evan Dellon, MD, MPH) |
|
Session (Time): |
Esophageal Diseases, Eosinophilic Esophagitis: Clinical – Distinguished Abstract Plenary (May 5, 8:52am CT) |
|
Title (Presenter): |
Primary Results of A Phase 1 Multicenter Open-Label Study of Antolimab, an Anti-Siglec-8 Antibody, for the Treatment of Patients with Chronic Gastrointestinal Symptoms and Elevated Gastric and/or Duodenal Mast Cells (Adam Bledsoe, MD) |
|
Session (Time): |
Functional GI and Motility Disorders, Functional Dyspepsia, Nausea and Vomiting (May 2, 5:15pm CT) |
|
Title (Presenter): |
EGID Biopsies Have Functionally Distinct and Activated Mast Cells that Contribute to Disease Pathogenesis and are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) (Brad Youngblood, PhD) |
|
Session (Time): |
Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic (May 4, 5:00pm CT) |
|
Title (Presenter): |
Mast Cells are Significantly Activated in Patients with Ulcerative Colitis and are Inhibited by an Anti-Siglec-8 Antibody, Antolimab (AK002) (Brad Youngblood, PhD) |
|
Session (Time): |
Basic Science, IBD: Cytokines, Signaling and Receptors (May 5, 12:30pm CT) |
|
Title (Presenter): |
Mast Cell Level and Clinical Correlates in Patients with Eosinophilic Gastritis and Gastroenteritis (Craig C. Reed, MD) |
|
Session (Time): |
Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic (May 4, 12:30pm CT) |
|
Title (Presenter): |
Establishment of Normal Tissue Mast Cell Levels in Gastric and Duodenal Biopsies of Patients Without Gastrointestinal Disease (Craig C. Reed, MD) |
|
Session (Time): |
Esophageal Diseases, Eosinophilic Esophagitis: Translational or Basic (May 4, 12:30pm CT) |
Following the presentations, the posters and slides will be available on the Allakos website.
About Allakos
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab has been tested in six clinical studies. In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.
###
Source: Allakos Inc.
|
Investor Contact: |
|
Media Contact: |
|
Adam Tomasi, President & COO |
|
Denise Powell |
|
ir@allakos.com |
|
denise@redhousecomms.com |